Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease (COVID-19) . At time of writing on 22 April 2020, the COVID-19 pandemic had resulted in approximatively 2.5 million reported cases worldwide with over 177,000 deaths .
Fast and reliable laboratory diagnostics for SARS-CoV2 [2-4] are important to support the rapid implementation of appropriate public health interventions. In the acute phase of COVID-19, laboratory diagnostics primarily rely on molecular methods [5,6]. In addition, serological assays are now being developed to allow epidemiological assessments through serosurveys, as well as retrospective diagnosis in targeted groups. The need for high quality testing kits suitable for in vitro diagnostics (IVD), automated laboratory equipment and laboratory information systems (LIS) is urgent. LIS, which record, manage, and store data are one of the key elements in reliable diagnostics with high throughput. Here we report on the evaluation of an automated serological screening approach for SARS-CoV-2 IgG and IgA antibodies.